Phase 2 N=75 OTO-201 for the Treatment of Otitis Externa
Otitis Externa
Primary: Otoscopic Examination: Tympanic Membrane — 6; 8; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Effectiveness of BoneSeal® on Bone Hemostats in Patients Undergoing Cardiothoracic Surgery
Coronary Artery Bypass Grafting
Primary: Ease of Use — 4; 1 units on a scale
Phase 2 N=420 RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
Respiratory Syncytial Virus Infections
Primary: PRNT (Subtype A) GMT — 300.5; 278.9; 311.9; 373.3 Titer
Phase 3 N=27 CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
Primary Immunodeficiency
Primary: Occurrence of All Treatment-emergent Adverse Events (TEAEs) — 8; 19; 22; 155 events
Phase 3 N=466 A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
Acne Vulgaris
Primary: Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12 — 13.95; 11.15 Lesion counts — p=0.0083
Phase 2 N=376 Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Ovarian Neoplasms
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Cohort A and…
N/A N=156 IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV
HIV · Depression
Primary: Depression Outcomes: Quick Inventory of Depression Symptomatology - Self Report (QIDS-SR) Score — 6.7; 10.6 units on a scale — p=0.01
Phase 4 N=108 Assess the Penumbra System in the Treatment of Acute Stroke
Ischemic Stroke
Primary: Good Functional Outcome as Defined by a Modified Rankin Score of 0-2 — 14; 19 Participants
Phase 2 N=39 Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
Idiopathic Pulmonary Fibrosis · Hypoxemia
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 8; 7; 4; 11 Participants
Phase 3 N=501 Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes
Otitis Media
Primary: Number of Subjects With Post-surgical Otorrhea — 383; 118 Participants
N/A N=49 Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)
Depression · Major Depressive Disorder
Primary: Quick Inventory of Depressive Symptomatology-Phase 1 — 11.06; 11.24 score on a scale
N/A N=566 The Videolaryngoscopy in Small Infants
Surgery · Anesthesia, Endotracheal
Primary: Number of Participants With Success in the First Attempt — 253; 243 Participants
Phase 2 N=24 HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Tumor Radiographic Response as Assessed by the RANO Criteria — 0; 0; 7; 17 Participants
N/A N=455 Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
Abdominal Aortic Aneurysm
Primary: Number of Patients With Absence of Aneurysm Related Complications (ARC) — 195; 175 Participants
Phase 3 N=377 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
Hepatitis C
Primary: Percentage of Participants Who Maintained a Sustained Virologic Response (SVR) Out of Those Who Achieved SVR12 in a Prior Study With an ABT-493- and/or…